AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Delcath Systems' HEPZATO Fuels Revenue Growth, Justifying Buy Rating
ByAinvest
Thursday, Aug 7, 2025 6:05 pm ET1min read
Delcath Systems' HEPZATO product has driven strong growth and expansion, leading to a Buy rating from H.C. Wainwright analyst Swayampakula Ramakanth. The company reported significant revenue growth in Q2 2025, attributed to HEPZATO sales and activation of multiple treatment centers. Medicaid participation and regional expansion are expected to enhance treatment volumes and broaden the market. A Buy rating and raised price target of $31 per share justify the bullish stance.
Delcath Systems, Inc. (Nasdaq: DCTH) reported significant financial results for the second quarter of 2025, highlighting strong revenue growth driven by its HEPZATO KIT™ product. The company reported total revenue of $24.2 million, a substantial increase from $7.8 million in the second quarter of 2024 [1].HEPZATO KIT™ revenue reached $22.5 million, up from $6.6 million in the same period last year, while CHEMOSAT® revenue stood at $1.7 million, compared to $1.2 million in the prior year. Gross margins improved to 86%, up from 80% in the same quarter last year. The company also reported a net income of $2.7 million, compared to a net loss of $13.7 million in the second quarter of 2024 [1].
Delcath Systems activated three new U.S. centers in the second quarter, bringing the total to 20 active centers, with an additional 10 centers accepting referrals. The company also announced its intention to enter into a Medicaid National Drug Rebate Agreement (NDRA) to expand patient access beginning July 1, 2025 [1].
The company's full-year 2025 financial guidance projects total CHEMOSAT and HEPZATO KIT revenue in the range of $93 to $96 million, an increase of more than 150% over 2024. Gross margins are expected to be in the range of 83% to 85% [1].
H.C. Wainwright analyst Swayampakula Ramakanth recently upgraded Delcath Systems to a Buy rating, with a price target of $31 per share, citing strong revenue growth and expansion plans for HEPZATO KIT™ [1].
References:
[1] https://investors.delcath.com/news-releases/news-release-details/delcath-systems-reports-second-quarter-2025-results-and-business
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet